Trauma and posttraumatic growth

PhDr. Marek Preiss Ph.D

Psychiatr. pro Praxi, 2009; 10(1): 8-11  

The article summarizes basic information about posttraumatic growth (PTG) in association with coping with trauma or critical situation. It presents options of measurement and working version of questionnaire method. Five categories of posttraumatic growth are described – relation to other people, new life perspectives, personality growth, spiritual change and life estimation.

Neuroimaging in psychiatric practice

MUDr. Tomáš Novák

Psychiatr. pro Praxi, 2009; 10(1): 12-16  

Introduction of computed tomography into clinical practice led to a revolution in diagnostics. First non-invasive brain visualization gave rise to expectations also in psychiatry. Despite a huge amount of data about the mental disorders provided by structural and functional neuroimaging techniques their benefit for routine psychiatric practice is still limited. Clear guidelines for brain imaging in psychiatry are lacking, except for dementia and emergency medical situation with consciousness disturbances or other neurological symptoms. This article is focused on the imaging techniques that are used and available in psychiatric practice.

Psychodynamic aspects of pharmacotherapy

MUDr. Peter Bobovník

Psychiatr. pro Praxi, 2009; 10(1): 17-19  

Incredible advances in neurobiological sciences and psychopharmocology could create an illusion of a psychiatrist as the objective scientist and of patients as only biological objects who simply respond biochemically to medication and get well. From a complex bio­psychosocial point of view we can consider also the psychological aspects of pharmacotherapy. The paper is centred on some transference and countertransference aspects of the doctor-patient relationship and on the unconcious meaning of medication for the patient. It also takes note of the possible contribution of resistence and negative therapeutic reply to noncompliance and hypersensitivity...

Antipsychotic medications of new generation as stimuli for new clinical thinking

MUDr. Ivan André PhD

Psychiatr. pro Praxi, 2009; 10(1): 20-21  

Present clinical practice with new types of antipsychotics does not bring only experience with the treatment itself but it has broader aspect reflecting multiple areas of clinical thinking. Practically oriented paper brings a review of some of these stimuli that are considered as relevant and useful for every day practice.

Treatment with atypical antipsychotic drugs and their selection based on the spectrum of side effects

doc. MUDr. Radovan Přikryl Ph.D

Psychiatr. pro Praxi, 2009; 10(1): 22-25  

The introduction of second-generation antipsychotics into clinical practice has significantly improved the treatment of schizophrenia. When selecting a particular drug, however, its side-effect profile has to be considered in addition to affecting the targeted symptoms. The main side effects of first-generation antipsychotics include extrapyramidal side effects and hyperprolactinaemia which, along with obesity, hyperglycaemia, hyperlipidaemia, or cardiac complications, are considered to be the major risks associated with the treatment with second-generation antipsychotics. The physician must carefully assess the benefit as well as possible risks related...

Sleep disorders in geriatric psychiatry and their treatment

MUDr.  Richard Krombholz, MUDr. Hana Drástová, PhDr. Václav Červenka

Psychiatr. pro Praxi, 2009; 10(1): 26-30  

Insomnia is the most common sleep disorder in elderly. Sleep disorders go along with fysiological ageing and also with mental disorder in old age. Use of benzodiazepine and non-benzodiazepine medications is risky to patients with organic afection of CNS. Long term use of this medicaments is risky to beginning of toleration and abuses. Melatonin is a new hypnotic with a specific influences. Causing no risk for abuse or dependence. The autors of this work would like to share of own experinces with this substance.

Pharmacotherapy of obsessive-compulsive disorder

MUDr. Jiřina Kosová

Psychiatr. pro Praxi, 2009; 10(1): 31-35  

Serotonine reuptake inhibitors (SRIs) are the first line of drugs in treatment of obsessive-compulsive disorder (OCD). Choice of SRI is determined by the side effect profile. High doses and longer trials are needed for adequate response. In responders, SRIs have to be continued in the same doses for a minimum of 1-2 years and may be lifelong in those with persistent symptoms and in those with multi­ple relapses. If the first SRI trial fails to elicit response, successive SRI trials have to be considered. Failure to respond to multiple SRI trials should lead to trials with clomipramine first and venlafaxine later. In non-responders and partial responders,...

Možnosti krizové pomoci pro lidi s psychózou

MUDr. Zuzana Foitová, MUDr. Jan Lorenc

Psychiatr. pro Praxi, 2009; 10(1): 36-38  

Slušný násilník vyprovokovaný slušnou ženou

PhDr. Tereza Soukupová

Psychiatr. pro Praxi, 2009; 10(1): 39-40  

Jak zvládat profesionální stres u pracovníků v oblasti duševního zdraví

MUDr. Karel Nešpor CSc

Psychiatr. pro Praxi, 2009; 10(1): 41-44  

Farmakoterapie nadměrné denní spavosti

MUDr. Iva Příhodová

Psychiatr. pro Praxi, 2009; 10(1): 44  

Regulační poplatky a psychiatrie

MUDr. Jiří Švarc Ph.D

Psychiatr. pro Praxi, 2009; 10(1): 48-50  

Poučení z e-STAR - historie se opakuje?

prof. MUDr. Eva Češková CSc

Psychiatr. pro Praxi, 2009; 10(1): 45-46  

Agresivita v dětství a její souvislosti - Léky ano, nebo ne…?

MUDr. Jaroslav Matýs

Psychiatr. pro Praxi, 2009; 10(1): 52-53  

Autodidaktický test č. 1 / 2009

Psychiatr. pro Praxi, 2009; 10(1): 54